Loading stock data…
MERCK KGAA I (MRK.DE)
€146.40+0.75 (+0.51%)
Market ClosedLast close Jun 29
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck KGaA in the Healthcare sector is trading at €146.40 with a market capitalization of $59.5B. Wall Street consensus targets €145.14 (14 analysts), implying a -0.9% move over the next 12 months. The stock is currently near its 52-week high of €147.85, remaining 24.6% above its 200-day moving average. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (EUR) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | €5.28B↑ | €5.25B↓ | €5.32B↑ | €5.25B↑ | €5.13B |
| Gross Profit | €3.15B↑ | €3.03B↓ | €3.21B↑ | €2.96B↓ | €3.06B |
| Operating Income | €1.01B↑ | €892.00M↓ | €1.21B↑ | €547.00M↓ | €943.00M |
| Net Income | €735.00M↑ | €652.00M↓ | €902.00M↑ | €319.00M↓ | €659.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€59.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.49
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Strong income play. Yield provides a meaningful total return floor.
161.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.53%
Volume
Today's trading volume
282,919
Recent News
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy
Company News for Jun 26, 2026
Companies in The News Are: BB, MKC, META, TECH, MKKGY
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The companies highlight expected synergies and accretion to Merck KGaA’s earnings following completion. For investors tracking Bio-Techne, the agreed $11.5b acquisition by Merck KGaA lands after a sharp move in the stock, with NasdaqGS:TECH up 22% over the past week and 47% over the past month. The...